Himisha Beltran
Overview
Explore the profile of Himisha Beltran including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
228
Citations
18584
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Pitzen S, Rudenick A, Qiu Y, Zhang W, Munro S, McCluskey B, et al.
Proc Natl Acad Sci U S A
. 2025 Feb;
122(6):e2415308122.
PMID: 39913208
Inhibiting the androgen receptor (AR) is effective for treatment of advanced prostate cancers because of their AR-dependent luminal epithelial cell identity. Tumors progress during therapy to castration-resistant prostate cancer (CRPC)...
3.
Sharifi M, Sperger J, Taylor A, Tippins K, Reese S, Carreno V, et al.
Cancer Discov
. 2025 Feb;
PMID: 39912912
The development of treatment resistance remains universal for patients with metastatic prostate cancer, driven by AR alterations and lineage state transitions. Identifying the evolution of lineage transitions in treatment resistance...
4.
Choucair K, Elliott A, Oberley M, Walker P, Salama A, Saeed A, et al.
BMJ Oncol
. 2025 Jan;
4(1):e000551.
PMID: 39885940
Objective: Cancer patients aged ≥80 years present unique characteristics affecting response to immune checkpoint inhibitors (ICIs), with unidentified molecular differences. This study aimed to explore potential biomarkers of response to...
5.
Lozada J, Elliott A, Evans M, Wacker J, Storey K, Egusa E, et al.
Cancer Res Commun
. 2025 Jan;
5(2):318-326.
PMID: 39874041
DLL3-targeted therapies have recently shown robust clinical efficacy in aggressive neuroendocrine cancers, positioning them to fulfill a great unmet need in these settings. Here, we examine the clinical and biological...
6.
Yu E, Rumble R, Agarwal N, Cheng H, Eggener S, Bitting R, et al.
J Clin Oncol
. 2025 Jan;
43(6):748-758.
PMID: 39787437
Purpose: To evaluate evidence on germline and somatic genomic testing for patients with metastatic prostate cancer and provide recommendations. Methods: A systematic review by a multidisciplinary panel with patient representation...
7.
Shore N, Nielsen S, Esplin E, Antonarakis E, Barata P, Beer T, et al.
JCO Oncol Pract
. 2024 Dec;
OP2400626.
PMID: 39700441
Indications for and implications of germline genetic testing (GGT) in patients with prostate cancer have expanded over the past decade, particularly related to precision therapies and management. GGT has become...
8.
9.
Knutson T, Luo B, Kobilka A, Lyman J, Guo S, Munro S, et al.
Nat Commun
. 2024 Dec;
15(1):10648.
PMID: 39663356
Circulating tumor DNA (ctDNA) in plasma cell free DNA (cfDNA) of cancer patients is associated with poor prognosis, but is challenging to detect from low plasma volumes. In metastatic castration-resistant...
10.
Bryce A, Agarwal N, Beltran H, Hussain M, Sartor O, Shore N, et al.
Cancer
. 2024 Dec;
131(1):e35612.
PMID: 39616467
Current US clinical practice guidelines for advanced prostate cancer management contain recommendations based on high-level evidence from randomized controlled trials; however, these guidelines do not address the nuanced clinical questions...